SOL-116 - BEYOND Bssl Targeting Therapy Towards Non-immunosuppressive Ra Treatment
- Coordinator
- Lipum AB, Sweden
- Runs
- 1 July 2026 to 30 June 2029
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €8.0m
- Partners
- 4 organisations in 3 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101287619
What the project is doing
In the project's own words, from its summary on CORDIS.
Rheumatoid arthritis (RA) remains a devastating autoimmune disease, affecting 5 million Europeans. Despite advances with biologics and JAK inhibitors, up to 40% of patients fail to respond or lose efficacy, while current treatments rely on broad immunosuppression, exposing patients to severe infections and long-term complications. There is an urgent unmet need for safer, more effective therapies. The SOL-116-BEYOND project directly addresses this gap by advancing SOL-116, a first-in-class humanized monoclonal antibody developed by Lipum, targeting bile salt-stimulated lipase (BSSL)—a previously overlooked driver of inflammation.
Unlike existing biologics, SOL-116 interrupts inflammation while sparing normal immune function. Building on strong preclinical data and Phase I results confirming safety, target engagement, and favorable pharmacokinetics, BEYOND will further develop SOL-116 through a phase 2 clinical trial, to demonstrate efficacy in the target population, enabling out licensing and further commercialisation. BEYOND is structured in three pillars: (1) a multicenter phase 2a clinical trial to establish efficacy and safety, (2) biomarker discovery and mechanistic insights to validate BSSL as a therapeutic target and enable patient stratification, and (3) health economics and patient-centered research to demonstrate societal and market value.
The lean, highly complementary consortium, comprising Lipum (developer of SOL-116), Age labs (Immunology/bioanalytics), Centre for Human Drug Research (clinical trials advisor) and MERAccess (health-economics), ensures scientific excellence, operational feasibility, and translational impact. BEYOND will pioneer safer, non-immunosuppressive RA treatment, strengthen Europe’s leadership in precision immunology, and position the consortium at the forefront of biotech innovation.
SOL-116 has the potential to reduce disability, improve quality of life, and achieve multi-billion-euro savings for European healthcare systems.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Lipum AB | Umea | Sweden | Coordinator |
| Stichting Centre for Human Drug Research | Leiden | Netherlands | Participant |
| Age Labs AS | Oslo | Norway | Participant |
| MERAccess AB | Tyreso | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI